Verzenio Plus Faslodex Improves Survival in Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer, Regardless of Menopausal Status
At the European Society for Medical Oncology 2019 Congress, Dr. Sledge presented overall survival results from the MONARCH 2 study, which used Verzenio (chemical name: abemaciclib) and Faslodex (chemical name: fulvestrant) to treat metastatic hormone-receptor-positive, HER2-negative breast cancer that was previously treated with hormonal therapy and had stopped responding. The women in the study were premenopausal, perimenopausal, or postmenopausal.
Listen to the podcast to hear Dr. Sledge explain:
the background of the MONARCH 2 study
how much overall survival was improved
the side effects seen in the study
what the results mean for people diagnosed with metastatic hormone-receptor-positive, HER2-negative breast cancer
Affiliations: Stanford University Medical Center, Stanford Cancer Institute, Immix Biopharma
Areas of specialization: breast cancer, medical oncology, biologic
treatments for breast cancer
Dr. George Sledge is professor of medicine and head of the Oncology Division at Stanford University. A former president of the American Society of Clinical Oncology, he specializes in breast cancer research. He has published extensively on the treatment of metastatic breast cancer and has been honored with numerous awards for his work.
— Last updated on February 11, 2022, 7:58 PM
This content made possible by Lilly Oncology.